156 related articles for article (PubMed ID: 20191497)
1. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity.
Curtis JR; Chen L; Harrold LR; Narongroeknawin P; Reed G; Solomon DH
Arthritis Care Res (Hoboken); 2010 Jan; 62(1):101-7. PubMed ID: 20191497
[TBL] [Abstract][Full Text] [Related]
2. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
[TBL] [Abstract][Full Text] [Related]
3. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
4. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
[TBL] [Abstract][Full Text] [Related]
5. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry.
Furst DE; Pangan AL; Harrold LR; Chang H; Reed G; Kremer JM; Greenberg JD
Arthritis Care Res (Hoboken); 2011 Jun; 63(6):856-64. PubMed ID: 21337725
[TBL] [Abstract][Full Text] [Related]
6. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
[TBL] [Abstract][Full Text] [Related]
7. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
Crane MM; Juneja M; Allen J; Kurrasch RH; Chu ME; Quattrocchi E; Manson SC; Chang DJ
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1646-55. PubMed ID: 26097059
[TBL] [Abstract][Full Text] [Related]
10. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects.
Smith CJ; Sayles H; Mikuls TR; Michaud K
Arthritis Res Ther; 2011; 13(5):R168. PubMed ID: 22008667
[TBL] [Abstract][Full Text] [Related]
11. Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil.
Acurcio FA; Machado MA; Moura CS; Ferre F; Guerra AA; Andrade EI; Cherchiglia ML; Rahme E
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1489-96. PubMed ID: 26814681
[TBL] [Abstract][Full Text] [Related]
12. Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study.
Michaud K; Pedro S; Wipfler K; Agarwal E; Katz P
Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1322-1331. PubMed ID: 33787086
[TBL] [Abstract][Full Text] [Related]
13. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
14. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
[TBL] [Abstract][Full Text] [Related]
15. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
16. Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort.
Fisher A; Bassett K; Wright JM; Brookhart MA; Freeman HJ; Dormuth CR
BMJ Open; 2014 Sep; 4(9):e005532. PubMed ID: 25270855
[TBL] [Abstract][Full Text] [Related]
17. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
[TBL] [Abstract][Full Text] [Related]
18. Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study.
Machado MA; Bernatsky S; Bessette L; Nedjar H; Rahme E
BMC Musculoskelet Disord; 2016 Jul; 17():298. PubMed ID: 27431503
[TBL] [Abstract][Full Text] [Related]
19. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
20. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
